Louise Ziegler1, Ashwini Gajulapuri2, Paolo Frumento3, Alice Bonomi4,5, Håkan Wallén1, Ulf de Faire5, Stefan Rose-John6, Bruna Gigante1,5. 1. Department of Clinical Science, Danderyd Hospital, S-182 88 Stockholm, Sweden. 2. Swetox, Academic Research Center for Chemicals, Health and Environment, Södertälje, Sweden. 3. Unit of Biostatistics at the Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 4. Unit of Biostatistics, Centro Cardiologico Monzino, IRCCS, Milan, Italy. 5. Unit of Cardiovascular Epidemiology, Karolinska Institutet, Stockholm, Sweden. 6. Department of Biochemistry, Christian-Albrechts-University, Kiel, Germany.
Abstract
Aims: The pro-inflammatory response to interleukin 6 (IL6) trans-signalling in atherosclerosis is driven by the IL6 and soluble IL6 receptor (sIL6R) binary complex. The binary IL6:sIL6R complex is inactivated by sgp130 through the formation of the ternary IL6:sIL6R:sgp130 complex. The aim of this study was to investigate if IL6 trans-signalling, estimated by a ratio between the binary and ternary complexes, associates with the risk of future cardiovascular events (CVE) in a Swedish cohort of 60-year-old men and women (n = 4232). Methods and results: Binary and ternary complex levels expressed in nanomol/Litre were derived from serum concentrations of IL6, sIL6R, and sgp130. Cox regression models were used to assess the risk of CVE (myocardial infarction, angina pectoris, and ischaemic stroke, n = 525), expressed as hazard ratio (HR) with 95% confidence interval (CI), associated with increasing circulating levels of the three molecules and with the binary/ternary complex ratio. Estimates were adjusted for the common cardiovascular (CV) risk factors. To assess the level of IL6-trans-signalling, we estimated the binary/ternary complex ratio and then analysed the association with CVE risk. A ratio higher than the median, representing a relative excess of the active binary complex was associated with increased CVE risk (adjusted HR 1.44, 95% CI 1.21-1.72). Conclusion: The ratio between the functional moieties of IL6 trans-signalling, IL6:sIL6R, and IL6:sIL6R:sgp130, was associated with CVE risk indicating that it could be a promising marker of CV risk and possibly be used in selecting patients for anti-inflammatory therapy.
Aims: The pro-inflammatory response to interleukin 6 (IL6) trans-signalling in atherosclerosis is driven by the IL6 and soluble IL6 receptor (sIL6R) binary complex. The binary IL6:sIL6R complex is inactivated by sgp130 through the formation of the ternary IL6:sIL6R:sgp130 complex. The aim of this study was to investigate if IL6 trans-signalling, estimated by a ratio between the binary and ternary complexes, associates with the risk of future cardiovascular events (CVE) in a Swedish cohort of 60-year-old men and women (n = 4232). Methods and results: Binary and ternary complex levels expressed in nanomol/Litre were derived from serum concentrations of IL6, sIL6R, and sgp130. Cox regression models were used to assess the risk of CVE (myocardial infarction, angina pectoris, and ischaemic stroke, n = 525), expressed as hazard ratio (HR) with 95% confidence interval (CI), associated with increasing circulating levels of the three molecules and with the binary/ternary complex ratio. Estimates were adjusted for the common cardiovascular (CV) risk factors. To assess the level of IL6-trans-signalling, we estimated the binary/ternary complex ratio and then analysed the association with CVE risk. A ratio higher than the median, representing a relative excess of the active binary complex was associated with increased CVE risk (adjusted HR 1.44, 95% CI 1.21-1.72). Conclusion: The ratio between the functional moieties of IL6 trans-signalling, IL6:sIL6R, and IL6:sIL6R:sgp130, was associated with CVE risk indicating that it could be a promising marker of CV risk and possibly be used in selecting patients for anti-inflammatory therapy.
Authors: María Ángeles Rodríguez-Hernández; David Carneros; María Núñez-Núñez; Ramón Coca; Rosario Baena; Gema M López-Ruiz; María Elena Cano-Serrano; Alberto Martínez-Tellería; Ana Fuentes-López; Juan Manuel Praena-Fernandez; Christoph Garbers; José Hernández-Quero; Federico García; Stefan Rose-John; Matilde Bustos Journal: Front Immunol Date: 2022-05-13 Impact factor: 8.786
Authors: Tomasz J Guzik; Saidi A Mohiddin; Anthony Dimarco; Vimal Patel; Kostas Savvatis; Federica M Marelli-Berg; Meena S Madhur; Maciej Tomaszewski; Pasquale Maffia; Fulvio D'Acquisto; Stuart A Nicklin; Ali J Marian; Ryszard Nosalski; Eleanor C Murray; Bartlomiej Guzik; Colin Berry; Rhian M Touyz; Reinhold Kreutz; Dao Wen Wang; David Bhella; Orlando Sagliocco; Filippo Crea; Emma C Thomson; Iain B McInnes Journal: Cardiovasc Res Date: 2020-08-01 Impact factor: 10.787
Authors: Ruth Davies; Jessica Williams; Katie Sime; Hyun-Sun Jin; Charlotte Thompson; Lauren Jordan; Derek Lang; Julian P Halcox; Elizabeth Ellins; Gareth W Jones; Simon A Jones; Stefan Rose-John; Anwen Williams; Ernest Choy Journal: Rheumatology (Oxford) Date: 2021-06-18 Impact factor: 7.580
Authors: Hilde E Groot; Lawien Al Ali; Iwan C C van der Horst; Remco A J Schurer; Hindrik W van der Werf; Erik Lipsic; Dirk J van Veldhuisen; Jacco C Karper; Pim van der Harst Journal: Clin Res Cardiol Date: 2018-10-26 Impact factor: 5.460